Autolus Therapeutics (AUTL)
(Delayed Data from NSDQ)
$2.47 USD
+0.14 (6.01%)
Updated Aug 11, 2025 04:00 PM ET
After-Market: $2.46 -0.01 (-0.40%) 5:30 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Autolus Therapeutics PLC Sponsored ADR's return on equity, or ROE, is -52.82% compared to the ROE of the Medical - Biomedical and Genetics industry of -61.64%. While this shows that AUTL has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
AUTL 2.47 +0.14(6.01%)
Will AUTL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AUTL based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for AUTL
Autolus Therapeutics Q2 2025 Earnings Preview
Autolus Therapeutics PLC (AUTL) Q2 2025 Earnings Report Preview: What To Look For
Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call ...
Analyst Reiterates Buy Rating on Autolus Therapeutics (AUTL) | AUTL Stock News